A Multi-Cohort Study of ApoE epsilon 4 and Amyloid-beta Effects on the Hippocampus in Alzheimer's Disease

Wasim Khan; Vincent Giampietro; Tobias Banaschewski; Gareth J Barker; Arun LW Bokde; Christian Buechel; Patricia Conrod; Herta Flor; Vincent Frouin; Hugh Garavan; Penny Gowland; Anreas Heinz; Bernd Ittermann; Herve Lemaitre; Frauke Nees; Tomas Paus; Zdenka Pausova; Marcella Rietschel; Michael N Smolka; Andreas Stroehle; Jeurgen Gallinat; Bruno Vellas; Hilkka Soininen; Iwona Kloszewska; Magda Tsolaki; Patrizia Mecocci; Christian Spenger; Victor L Villemagne; Colin L Masters; J-Sebastian Muehlboeck; Lars Backman; Laura Fratiglioni; Gregoria Kalpouzos; Lars-Olof Wahlund; Gunther Schumann; Simon Lovestone; Steven CR Williams; Eric Westman; Andrew Simmons

Journal article

A Multi-Cohort Study of ApoE epsilon 4 and Amyloid-beta Effects on the Hippocampus in Alzheimer's Disease

Wasim Khan, Vincent Giampietro, Tobias Banaschewski, Gareth J Barker, Arun LW Bokde, Christian Buechel, Patricia Conrod, Herta Flor, Vincent Frouin, Hugh Garavan, Penny Gowland, Anreas Heinz, Bernd Ittermann, Herve Lemaitre, Frauke Nees, Tomas Paus, Zdenka Pausova, Marcella Rietschel, Michael N Smolka, Andreas Stroehle Show all

Journal of Alzheimer's Disease | IOS PRESS | Published : 2017

DOI: 10.3233/JAD-161097

University of Melbourne Researchers

Colin Masters Author Florey Department of Neuroscience and Mental Health

Victor Villemagne Author Medicine - Austin Health

Grants

Awarded by InnoMed, (Innovative Medicines in Europe) an Integrated Project - European Union of the Sixth Framework program

Awarded by European Community's Sixth Framework Program

Awarded by coordinated project ADAMS

Funding Acknowledgements

Data used in the preparation of this study was obtained from the AddNeuroMed study which was supported by InnoMed, (Innovative Medicines in Europe) an Integrated Project funded by the European Union of the Sixth Framework program priority FP6-2004-LIFESCIHEALTH-5, Life Sciences, Genomics and Biotechnology for Health, Health Research Council of Academy of Finland (HS), The Gamla Tjanarinnor Foundation, The Swedish Alzheimer's Association and Swedish Brain Power.r Data used in the preparation of this study were obtained from the Swedish National Study of Aging and Care in Kungsholmen (SNAC-K) which was supported by Stiftelsen for Gamla Tjanarinnor and Sigurd och Elsa Goljes Minne, the Swedish Research Council, the Swedish Council for Working Life and Social Research, Swedish Brain Power, an Alexander von Humboldt Research Award, and a donation from the af Jochnick Foundation.r Data used in the preparation of this study were obtained for the IMAGEN study which was supported by the IMAGEN project, which receives research funding from the European Community's Sixth Framework Program (LSHM-CT-2007-037286) and coordinated project ADAMS (242257), as well as the NIHR Biomedical Research Centre for Mental Health and NIHR Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, Psychology, and Neuroscience (IoPPN), King's College London, Alzheimer Research UK and the IMI funded European Medical Information Framework.